Press Releases Keyword Search Year None202420232022202120202019201820172016201520142013 October 22, 2024 Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update October 21, 2024 Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics October 18, 2024 Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept October 3, 2024 Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust August 28, 2024 Editas Medicine to Participate in Upcoming Investor Conferences August 7, 2024 Editas Medicine Announces Second Quarter 2024 Results and Business Updates July 31, 2024 Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update June 14, 2024 Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress May 14, 2024 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June May 10, 2024 Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last »
October 22, 2024 Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 21, 2024 Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 18, 2024 Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 3, 2024 Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
July 31, 2024 Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
June 14, 2024 Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
May 14, 2024 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 10, 2024 Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting